Quest Laboratories Ltd Hits Upper Circuit Amid Strong Buying Pressure

Upper Circuit Triggered on Strong Demand

On 13 Mar 2026, Quest Laboratories Ltd’s stock price escalated by ₹5.6, closing at ₹117.6, the highest price of the day and the maximum permissible increase within the 5% price band. The stock’s low for the session was ₹110.0, indicating a strong upward momentum throughout the trading day. The total traded volume stood at 0.288 lakh shares, generating a turnover of ₹0.33 crore, signalling active participation despite the company’s micro-cap status with a market capitalisation of ₹193.00 crore.

The upper circuit hit is a clear indication of overwhelming demand that outstripped available supply, leading to a regulatory freeze on further price appreciation for the day. This freeze is designed to curb excessive volatility and maintain orderly market conditions. The unfilled demand suggests that investors are keenly optimistic about the company’s prospects, driving the stock to its daily maximum gain.

Performance Context Within Sector and Market

Quest Laboratories’ price movement contrasts with the broader Pharmaceuticals & Biotechnology sector, which declined by 0.60% on the same day. The Sensex also fell by 0.84%, highlighting the stock’s relative outperformance amid a generally bearish market environment. This divergence emphasises the stock’s appeal as a potential outperformer within its industry and the wider market.

Technical indicators provide further insight into the stock’s momentum. The last traded price (LTP) of ₹117.6 is above the 5-day, 50-day, 100-day, and 200-day moving averages, signalling a sustained uptrend over multiple time horizons. However, it remains below the 20-day moving average, suggesting some near-term resistance that may require monitoring by investors.

Investor Participation and Liquidity Analysis

Despite the strong price rally, investor participation has shown signs of moderation. The delivery volume on 12 Mar 2026 was 27,600 shares, representing a sharp decline of 66.08% compared to the 5-day average delivery volume. This drop in delivery volume indicates that while the stock is experiencing buying pressure, fewer investors are holding shares for the long term, possibly reflecting speculative interest or short-term trading activity.

Liquidity remains adequate for trading, with the stock’s traded value representing approximately 2% of its 5-day average traded value. This liquidity level supports trade sizes of around ₹0.02 crore without significant market impact, making it accessible for retail and institutional investors alike.

Mojo Score Upgrade Reflects Strong Buy Sentiment

Quest Laboratories Ltd’s recent upgrade in its Mojo Grade from Buy to Strong Buy on 12 Mar 2026, with a Mojo Score of 81.0, reinforces the positive outlook for the stock. This upgrade reflects improved fundamentals, technical strength, and favourable market positioning within the Pharmaceuticals & Biotechnology sector. The Mojo grading system, widely respected for its comprehensive analysis, indicates that the stock is well poised for further appreciation, supported by robust financial metrics and quality assessments.

As a micro-cap stock, Quest Laboratories offers investors exposure to a niche segment with potential for significant growth, albeit with higher volatility. The upgrade signals increased confidence from analysts and market participants, which may attract further buying interest in the near term.

Outlook and Investor Considerations

While the upper circuit hit and strong buying pressure are encouraging signs, investors should remain mindful of the stock’s liquidity constraints and the recent decline in delivery volumes. The stock’s performance relative to the sector and Sensex suggests it is a standout performer, but the broader market environment remains challenging.

Technical traders may watch the 20-day moving average as a key resistance level, while fundamental investors should consider the company’s micro-cap status and associated risks. The regulatory freeze following the upper circuit hit ensures price stability but also limits immediate upside, making the next trading sessions critical for confirming the sustainability of the rally.

Conclusion: A Stock to Watch Closely

Quest Laboratories Ltd’s upper circuit hit on 13 Mar 2026 highlights the stock’s strong appeal amid a subdued market backdrop. The combination of a significant price gain, regulatory price freeze, and a Mojo Grade upgrade to Strong Buy positions the stock as a compelling candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology micro-cap space.

However, the decline in delivery volumes and the stock’s liquidity profile warrant cautious optimism. Investors should monitor upcoming trading sessions for confirmation of sustained buying interest and evaluate the stock’s technical levels alongside fundamental developments. Overall, Quest Laboratories Ltd remains a noteworthy contender for those looking to capitalise on emerging opportunities within the sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →